Successful Discontinuation of Infliximab in a Refractory Case of Vasculo-Behçet Disease

Reports have shown that antitumor necrosis factor alpha (anti-TNF-α) agents including infliximab (IFX) can dramatically suppress the disease activity of refractory vasculo-Behçet disease (vasculo-BD). However, it is completely unknown whether we can discontinue anti-TNF-α agents under clinical remis...

Full description

Saved in:
Bibliographic Details
Main Authors: Akihiro Nakamura, Tomoya Miyamura, Eiichi Suematsu
Format: Article
Language:English
Published: Wiley 2016-01-01
Series:Case Reports in Rheumatology
Online Access:http://dx.doi.org/10.1155/2016/1467583
Tags: Add Tag
No Tags, Be the first to tag this record!